Neuca

Neuca Financing Cash Flow

The Net Financing Cash Flow of Neuca (NEU.WA) as of Oct 22, 2026 is -144.95 M PLN. In the previous year, Net Financing Cash Flow was 139.62 M PLN — a change of -203.82% (lower).

Financing Cash Flow

-144.95 MPLN

YoY

-203.82%

Last updated:

Net Financing Cash Flow of Neuca is 2025 -144.95 M PLN. Net Financing Cash Flow of Neuca was 2024 139.62 M PLN. It decreases by -203.82% lower compared to the previous year.

The Neuca Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
22.77 M PLN
Jan 1, 2019
-20.00 M PLN
Jan 1, 2020
-234.07 M PLN
Jan 1, 2021
-112.76 M PLN
Jan 1, 2022
-6.64 M PLN
Jan 1, 2023
-139.09 M PLN
Jan 1, 2024
139.62 M PLN
Jan 1, 2025
-144.95 M PLN
The Neuca Financing Cash Flow history
YEARFinancing Cash FlowYoY
-144.95 MPLN-203.82%
139.62 MPLN-200.38%
-139.09 MPLN+1,996.04%
-6.64 MPLN-94.11%
-112.76 MPLN-51.83%
-234.07 MPLN+1,070.44%
-20.00 MPLN-187.81%
22.77 MPLN-121.08%
-108.04 MPLN+6.90%
-101.06 MPLN+9.97%
-91.89 MPLN-328.64%
40.19 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Net Financing Cash Flow of Neuca is -144.95 M PLN in 2025.

Net Financing Cash Flow of Neuca changed from 139.62 M PLN to -144.95 M PLN, representing a -203.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Neuca since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Neuca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Neuca

All Key Metrics — Neuca